In a report published on Tuesday, Oppenheimer analyst David Ferreiro initiated coverage on Neurocrine Biosciences NBIX with a rating of Outperform and a price target of $16.
In the report, Oppenheimer stated, "in the ph.III endometriosis results (1H14) and the ph.IIb fibroids results (2H14). Given these blockbuster opportunities, we envisage significant upside on positive outcomes. We view secondary asset, NBI-98854, for tardive dyskinesia (TD), as risky, but believe only modest value is baked in."
Neurocrine Biosciences closed on Monday at $12.72.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in